| Active substance |
Imatinib |
| Also known as |
STI571 |
| Blood pressure |
Can cause changes in blood pressure, monitoring advised |
| Chemical name |
4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide |
| Dosage (medical) |
Typically 400-800 mg per day, depending on the condition being treated |
| Dosage (sports) |
Not applicable as it is not used for performance enhancement |
| Effects |
Treats certain types of cancer by blocking the action of the abnormal protein that signals cancer cells to multiply |
| Formula |
C29H31N7O |
| Half-life |
Approximately 18 hours |
| Hepatotoxicity |
Low, but liver function tests are recommended |
| Lab Test |
Monitoring of complete blood counts and liver function tests are advised |
| Main action |
Inhibits the Bcr-Abl tyrosine kinase |
| Side effects |
Nausea, vomiting, edema, muscle cramps, musculoskeletal pain, diarrhea, rash, fatigue, abdominal pain |
| Storage conditions |
Store at room temperature, away from moisture and heat |
| Strength |
400mg |
| Substance class |
Tyrosine kinase inhibitor |
| Trade name |
Gleevec (USA), Glivec (Europe and Australia) |
| Use in sports |
None, not used as a performance-enhancing drug |
| Water Retention |
Yes, can cause fluid retention |
| Manufacturer |
Natco Pharmaceuticals Ltd. |
| Packing |
10 caps/blister |
